Oncotelic Therapeutics Advances CNS Drug Delivery Strategy with $12.5M Monetization of N2B System

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its position in one of biotechnology's most persistent and commercially significant challenges: drug delivery to the central nervous system (CNS). As the industry increasingly recognizes the blood-brain barrier (BBB) as a primary constraint in neurological drug development, companies developing delivery-focused platforms are gaining increased attention across both biodefense and healthcare markets.

Oncotelic completed a $12.5 million monetization of its N2B CNS delivery system with Lunai Bioworks, targeting Alzheimer's and biodefense applications. The deal grants field-specific IP rights while preserving Oncotelic's development in other CNS indications. This move aligns with the rising industry focus on blood-brain barrier bypass technologies and platform-based CNS drug delivery.

According to a recent BioMedWire editorial, "CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities," this shift is highlighted, noting that the BBB prevents the majority of therapeutics from reaching the brain and contributes to higher failure rates in CNS drug pipelines. The editorial can be accessed at https://nnw.fm/CdAQn.

For more information about Oncotelic Therapeutics, visit the company's newsroom at https://nnw.fm/OTLC.